These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 37654194)

  • 1. Utilization and toxicity patterns of 2-weekly (Q2W) versus 4-weekly (Q4W) nivolumab for treatment of adjuvant and metastatic melanoma at BC cancer.
    Truong J; Yeung SST; Kletas V; de Lemos M; Schaff K; Nakashima L
    J Oncol Pharm Pract; 2024 Sep; 30(6):1016-1022. PubMed ID: 37654194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer.
    Long GV; Tykodi SS; Schneider JG; Garbe C; Gravis G; Rashford M; Agrawal S; Grigoryeva E; Bello A; Roy A; Rollin L; Zhao X
    Ann Oncol; 2018 Nov; 29(11):2208-2213. PubMed ID: 30215677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective.
    Bi Y; Liu J; Furmanski B; Zhao H; Yu J; Osgood C; Ward A; Keegan P; Booth BP; Rahman A; Wang Y
    Ann Oncol; 2019 Apr; 30(4):644-651. PubMed ID: 30715147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective comparison of a weight-based dose every 2 weeks with a fixed dose every month: a real-life analysis of nivolumab in the treatment of advanced melanoma.
    Leroy M; Desmedt E; Deramoudt L; Vasseur M; Odou P; Béhal H; Décaudin B; Mortier L; Simon N
    Melanoma Res; 2024 Jun; 34(3):258-264. PubMed ID: 38489575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of safety outcomes between nivolumab regimens with differing dosing patterns.
    Elijah J; Puzanov I; Cresanti B; Hamad L; Attwood K; Catalfamo K; Riebandt G
    J Oncol Pharm Pract; 2024 Jul; ():10781552241264817. PubMed ID: 39043219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.
    Rozeman EA; Menzies AM; van Akkooi ACJ; Adhikari C; Bierman C; van de Wiel BA; Scolyer RA; Krijgsman O; Sikorska K; Eriksson H; Broeks A; van Thienen JV; Guminski AD; Acosta AT; Ter Meulen S; Koenen AM; Bosch LJW; Shannon K; Pronk LM; Gonzalez M; Ch'ng S; Grijpink-Ongering LG; Stretch J; Heijmink S; van Tinteren H; Haanen JBAG; Nieweg OE; Klop WMC; Zuur CL; Saw RPM; van Houdt WJ; Peeper DS; Spillane AJ; Hansson J; Schumacher TN; Long GV; Blank CU
    Lancet Oncol; 2019 Jul; 20(7):948-960. PubMed ID: 31160251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study.
    Cantini L; Paoloni F; Pecci F; Spagnolo F; Genova C; Tanda ET; Aerts S; Rebuzzi SE; Fornarini G; Zoratto F; Fancelli S; Lupi A; Della Corte CM; Parisi A; Bennati C; Ortega C; Atzori F; Piovano PL; Orciuolo C; De Tursi M; Ghidini M; Botticelli A; Scagnoli S; Belluomini L; Leporati R; Veccia A; Di Giacomo AM; Festino L; Cortinovis D; Acquati M; Filetti M; Giusti R; Tucci M; Sergi MC; Garutti M; Puglisi F; Manglaviti S; Citarella F; Santoni M; Rijavec E; Lo Russo G; Santini D; Addeo A; Antonuzzo L; Indini A; Rocchi MBL; Cortellini A; Grossi F; Ascierto PA; Aerts JGJV; Berardi R
    J Natl Cancer Inst; 2023 Jul; 115(7):796-804. PubMed ID: 37042716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types.
    Zhao X; Shen J; Ivaturi V; Gopalakrishnan M; Feng Y; Schmidt BJ; Statkevich P; Goodman V; Gobburu J; Bello A; Roy A; Agrawal S
    Ann Oncol; 2020 Feb; 31(2):302-309. PubMed ID: 31959348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma.
    Samlowski W; Robert NJ; Chen L; Schenkel B; Davis C; Moshyk A; Kotapati S; Poretta T; Weber JS
    Cancer Med; 2023 Feb; 12(3):2378-2388. PubMed ID: 35880244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review.
    Sise ME; Seethapathy H; Reynolds KL
    Oncologist; 2019 Jun; 24(6):735-742. PubMed ID: 30902916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
    Chang CY; Park H; Malone DC; Wang CY; Wilson DL; Yeh YM; Van Boemmel-Wegmann S; Lo-Ciganic WH
    JAMA Netw Open; 2020 Mar; 3(3):e201611. PubMed ID: 32211869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies.
    Wu CE; Yang CK; Peng MT; Huang PW; Chang CF; Yeh KY; Chen CB; Wang CL; Hsu CW; Chen IW; Lin CT; Ueng SH; Lin G; Lin YF; Cheng CY; Chang JW
    BMC Cancer; 2020 Oct; 20(1):1018. PubMed ID: 33087090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of emergency department visits and immune-related adverse effects (irAEs) in patients treated with nivolumab.
    Kudu E; Akdag G; Yildirim ME
    Support Care Cancer; 2024 Sep; 32(10):646. PubMed ID: 39251491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefit-risk assessment of nivolumab 240 mg flat dose relative to 3 mg/kg Q2W regimen in Japanese patients with advanced cancers.
    Bei D; Osawa M; Uemura S; Ohno T; Gobburu J; Roy A; Hasegawa M
    Cancer Sci; 2020 Feb; 111(2):528-535. PubMed ID: 31773815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports.
    Yoshino K; Nakayama T; Ito A; Sato E; Kitano S
    BMC Cancer; 2019 Oct; 19(1):1019. PubMed ID: 31664934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab.
    Yamauchi I; Yasoda A; Matsumoto S; Sakamori Y; Kim YH; Nomura M; Otsuka A; Yamasaki T; Saito R; Kitamura M; Kitawaki T; Hishizawa M; Kawaguchi-Sakita N; Fujii T; Taura D; Sone M; Inagaki N
    PLoS One; 2019; 14(5):e0216954. PubMed ID: 31086392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between immune-related adverse events and efficacy of PD-1 inhibitors in Chinese patients with advanced melanoma.
    Zhao JJ; Wen XZ; Ding Y; Li DD; Zhu BY; Li JJ; Weng DS; Zhang X; Zhang XS
    Aging (Albany NY); 2020 Jun; 12(11):10663-10675. PubMed ID: 32516130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.
    Lebbé C; Meyer N; Mortier L; Marquez-Rodas I; Robert C; Rutkowski P; Menzies AM; Eigentler T; Ascierto PA; Smylie M; Schadendorf D; Ajaz M; Svane IM; Gonzalez R; Rollin L; Lord-Bessen J; Saci A; Grigoryeva E; Pigozzo J
    J Clin Oncol; 2019 Apr; 37(11):867-875. PubMed ID: 30811280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of clinical safety between standard versus extended interval dosing of immune checkpoint inhibitors: a real-world retrospective cohort study.
    Colard-Thomas J; Manceron C; Duflos C; Herman F; Simon M; Maria ATJ; Faillie JL; Viala M; Palassin P
    ESMO Open; 2023 Dec; 8(6):102070. PubMed ID: 37988951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Zimmer L; Livingstone E; Hassel JC; Fluck M; Eigentler T; Loquai C; Haferkamp S; Gutzmer R; Meier F; Mohr P; Hauschild A; Schilling B; Menzer C; Kieker F; Dippel E; Rösch A; Simon JC; Conrad B; Körner S; Windemuth-Kieselbach C; Schwarz L; Garbe C; Becker JC; Schadendorf D;
    Lancet; 2020 May; 395(10236):1558-1568. PubMed ID: 32416781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.